FREE ELECTRONIC LIBRARY - Dissertations, online materials

Pages:   || 2 |

«LAW OFFICE OF T. SPENCE CHUBB 1025 Connecticut Avenue, N.W., Suite 1000 Washington, DC 20036 (703) 623-7739 tschubb The Honorable ...»

-- [ Page 1 ] --


1025 Connecticut Avenue, N.W., Suite 1000

Washington, DC 20036

(703) 623-7739


The Honorable Lisa R. Barton March 8, 2016

Secretary to the Commission

U.S. International Trade Commission

500 E Street, SW

Washington, DC 20436

Re: Certain Nanopores and Products Containing Same; Docket No. 3123 – Public Interest Comments

Dear Secretary Barton:

Proposed respondents Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (collectively, “Oxford Nanopore”) respectfully submit the following comments in response to the Commission’s Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest (81 Fed. Reg. 10278 (February 29, 2016)).

Oxford Nanopore categorically denies that it is liable for infringing the asserted patents. The allegations of Complainant Illumina, Inc. (“Illumina”) are based on nothing more than unsubstantiated speculation, with no proof that the current version of Oxford Nanopore’s MinION device has any relationship to the technology claimed in the asserted patents.1 The relief requested by Complainants raises substantial public interest concerns because an exclusion order against Oxford Nanopore’s devices would be detrimental to consumers, to competitive conditions in the United States, and to the public health, safety and welfare. The exclusion of the MinION would interfere with important on-going medical, scientific and industrial research because neither Illumina nor any other supplier can fill the resulting void.2 Without limiting Oxford Nanopore’s assertion that it is not liable for infringement, Oxford Nanopore’s products, the MinION and PromethION, are comprised of much more than a nanopore. Each device includes proprietary chemical, fluidics, semiconductor, software control, signal analysis, and reporting technologies. The asserted patents, even if valid and construed in extremis, only cover the single-use disposable nanopore flowcell used with the device and not the device itself. Moreover, the asserted patents relate to a single, specific type of nanopore comprised of Mycobacterium smegmatis (Msp) porin. Oxford Nanopore’s devices can be configured to work with any pore. Moreover, despite Illumina’ assertions, the MspA pore is not particularly special nor is it the best pore for use in DNA sequencing. Oxford Nanopore continuously explores a range of nanopore designs and develops “wild-type” nanopores into more efficacious structures.

Indeed, Oxford Nanopore, together with scientists at Vrje Universiteit Brussel and the University of London, has developed a proprietary nanopore based upon a non-Msp protein. See “Structural and mechanistic insights into the bacterial amyloid secretion channel CsgG,” Goyal et al., Nature, 516, 250-253 (Dec. 11, 2014), http://www.nature.com/nature/journal/v516/n7530/full/nature13768.html.

Although a proto-type of a PromethION (without nanopores) was shown at a conference in the United States, Oxford Nanopore’s PromethION has never been imported into the United States; the only Oxford Nanopore device that could be at issue in this proceeding is the MinION.

Moreover, nanopore technology, a field in which Oxford Nanopore is the world leader, is a revolutionary and disruptive technology3 that represents a significant competitive threat to Illumina’s monopolistic hold on the U.S. sequencing market. Nanopore technology has the potential to replace traditional Sequencing-by-Synthesis (SBS) technology on which Illumina’s instruments are based and to greatly expand the base of potential users and applications. Illumina acquired the asserted patents, and has filed this ITC action, to stifle competition.

A. The Relief Sought Would Harm Public Health, Safety and Welfare.

Weighing in at less than 100 grams, Oxford Nanopore’s pocket-sized MinION is the world’s first portable, real-time DNA sequencing device and the only such device currently available. It’s so small scientists can easily take it out into the field, like they did during the Ebola outbreak. In contrast, Illumina’s typical machine is the size of a refrigerator and desktop copier. The MinION also is the only sequencer that costs less than $1,000. Other sequencers cost from several tens of thousands of dollars to several million dollars for Illumina’s most powerful system.

The MinION is a research tool currently used in biological research, environmental science, pathogen analysis, cancer research, and an increasing number of other fields. This broad base of research using Oxford Nanopore technology is starting to translate to actual and potential real-world, field-based applications in public health (e.g. surveillance of Ebola, Zika, salmonella, and flu viruses), environmental safety (e.g. rapid identification of species in water or other samples), healthcare (e.g.

rapid detection of cancer and genetic abnormalities), and security (e.g. development of bioterrorism countermeasures). The MinION is being used by dozens of leading U.S. universities (often funded by the National Science Foundation or the National Institutes of Health), as well as 68 U.S. agencies and departments, including the Centers for Disease Control, Defense Forensic Science Center, NASA Johnson Space Center, U.S. Army, U.S. Air Force, Los Alamos National Lab, U.S. Department of Agriculture, and the Smithsonian Institution.

The MinION is being used to conduct ground-breaking field research aimed at breaking the chain of transmission of viruses such as Ebola and Zika, research that could not be completed as rapidly and in the field without MiniONs. Traditional sequencing technology often requires time to ship blood samples from the field back to a sophisticated laboratory for analysis, and then ship results from the laboratory to the field. In contrast, the field deployable MinION device can identify viruses and mutations in viruses in real time—researchers battling the Zika virus have reported detection in as little as four minutes from starting a MinION experiment. Surveillance data shows that this allows health workers combating emergencies in the field to quickly identify signatures of host adaptation, identify and monitor diagnostic targets, and characterize responses to vaccines and treatments. In the U.S., blood samples must be sent to the Centers for Disease Control, and it can take up to three weeks from the onset of infection for the test results to arrive.4 Scientists hope and believe the MinION will eventually be “...a device that can detect all pathogens—virus, bacteria, fungus, parasite known or A disruptive innovation is an innovation with new properties when compared to the incumbent that creates a new market and value network and eventually disrupts an existing market and value network, displacing established market leaders and alliances and having significant societal impact.

See “New Rapid Zika Test Could Contain Spread of Disease,” KQED SCIENCE, Sheraz Sadiq (February 4, 2016).

unknown—in a single test.”5 Beyond the initial test, collecting DNA information allows broad genomic surveillance of an infectious disease and the MinION can allow rapid deployment and turnaround of results in remote or diverse locations for this purpose.6 Unlike Illumina’s machines, which break DNA into small fragments and use software to align fragments after sequencing, Oxford Nanopore’s technology sequences very long DNA fragments, that has implications across a variety of processes and applications. Scientists increasingly agree that understanding the complexity of cancer requires identification of structural variants in DNA sequencing. According to Scientists at Johns Hopkins, structural variants remain difficult to reliably detect with short-read technology (such as Illumina’s SBS-based technology). Their research, summarized in the article, states that the MinION, because of its ability to sense long DNA fragments, may improve detection of structural variants. “Given the speed, small footprint, and low capital cost, nanopore sequencing could become the ideal tool for the low-level detection of cancer-associated structural variants needed for molecular relapse, early detection, or therapeutic monitoring.”7 Illumina’s assertion that “competing products are otherwise available from Illumina and other sources” is completely specious—a statement analogous to arguing for restricting the trade of smartphones because mainframe and desktop computers are available. The technologies are not interchangeable, and neither Illumina nor any other provider offers a sequencer comparable to the MinION that includes all the properties of portability, real-time data streaming, direct electronic sensing, and long read lengths.

Indeed, Illumina has not published any data proving that it has ever successfully and accurately sequenced DNA using nanopore technology, even in the laboratory much less in the field.

Nor has Illumina demonstrated any ability to embody nanopore technology in a practical commercial format. And even if Illumina could somehow get a nanopore sequencer ready for market, it would have issues commercializing it. Oxford Nanopore believes it would be difficult for Illumina to offer a competing nanopore product in light of patents owned by Oxford Nanopore, Harvard University and University of California.

Excluding Oxford Nanopore’s devices would harm the public interest. Interruption of the availability of MinION devices would interfere with research vital to the public interest. Researchers and industry in the United States would be denied the portable, real-time sequencing capabilities that only the MinION can offer. U.S. security, U.S. public health, and U.S. research, including more than 800 U.S. researchers, would be placed at a significant disadvantage compared to their colleagues and See “Ebola, Zika and More: Designing One Test to Catch Them All” www.UCSF.edu, Jyoti Madhusoodanan (February 11, 2016)(quoting Dr. Charles Chiu, an associate professor of Laboratory Medicine and director of the UCSFAbbott Viral Diagnostics and Discovery Center).

See, “Real-time, portable genome sequencing for Ebola surveillance,” Nature, 530, 228-232, Quick et al (Feb. 11, 2016), available at http://www.nature.com/nature/journal/v530/n7589/full/nature16996.html; “Real-time digital pathogen surveillance—the time is now,” Genome Biology 15:155, Gardy et al (July 30, 2015), available at http://genomebiology.biomedcentral.com/articles/10.1186/s13059-015-0726-x.

“Hopkins Team Assesses Oxford Nanopore MinION for Cancer Structural Variant Detection,” Julia Karow (Oct 5, 2015), available at https://www.genomeweb.com/sequencing-technology/hopkins-team-assesses-oxford-nanoporeminion-cancer-structural-variant.

competitors throughout the rest of the world who will have continued access to Oxford Nanopore’s unique devices.

B. Illumina Seeks To Stifle Emerging Competition and To Enhance Its Monopoly In The Conventional DNA Sequencing Market.

Illumina is a $23 billion company that for many years controlled an ever-increasing majority of the DNA sequencing market. With upwards of 75% market share, “owing to the company’s essential monopoly of the high-throughput portion of the market, over 90% of sequenced genetic material likely comes off an Illumina machine.”8 Until recently, the DNA sequencing market consisted entirely of complex, non-portable and expensive devices capable of sequencing only small fragments of DNA; Illumina dominates that market. Nanopore technology is a revolutionary sequencing technology, and while Oxford Nanopore is small emerging company, it is the only competitor with a commercial product utilizing nanopore technology. Indeed, Oxford Nanopore’s MinION device has been described as “a radical step in the evolution of reading DNA, a smartphone in a world of supercomputers.”9 Illumina paints Oxford Nanopore as unfairly competing in the market for nanopore sequencing, but the facts do not support its allegations. For a decade, Oxford Nanopore has been collaborating with and supporting research at Harvard, University of California Santa Cruz, and Oxford and has collaborations with approximately 30 institutions around the world, complemented by substantial investment in internal research and development. It is the only company to successfully develop a nanopore-based sequencer. Oxford Nanopore has a broad patent portfolio, through in-house development and licensing agreements with third parties.

In its quest to monopolize the market for conventional DNA sequencing devices, Illumina historically has paid scant attention to and made minimal investments in nanopore technology.

Contrary to the picture that Illumina tries to paint in its Complaint, Illumina holds very little IP in the nanopore space and, to date, has not shown any related innovation or that it has been successful in exploiting the little nanopore IP that it does own. Indeed, all of Illumina’s nanopore-specific IP was filed or acquired by Illumina subsequent to 2008 when Oxford Nanopore gave Illumina confidential presentations of its nanopore technology prior to the two parties entering into a Commercialization Agreement. Shortly after the Commercialization Agreement was consummated, Illumina performed a freedom to operate exercise purportedly on Oxford Nanopore’s behalf and after representing that it did not intend to develop its own nanopore product. The freedom to operate exercise did not reveal any IP held by Illumina relating to nanopore technology.

Pages:   || 2 |

Similar works:

«Compilation of Sample Mediation Clauses Alternative Dispute Resolution Committee of the New York City Bar Association June 8, 2016 THE ASSOCIATION OF THE BAR OF THE CITY OF NEW YORK 42 West 44th Street, New York, NY 10036-6689 www.nycbar.org Introduction This Compilation of Sample Mediation Clauses was created by a subcommittee of the Alternative Dispute Resolution (“ADR”) Committee of the New York City Bar Association, with the goal of providing practitioners with useful language to...»

«Amos Starr Police Brutality and Civil Rights Violations in Mid-20th Century Alabama Mado E. Martinez, Northeastern University School of Law ’15 Civil Rights and Restorative Justice Clinic Summer 2014 (Working Document) TABLE OF CONTENTS I. INTRODUCTION II. THE VICTIM, AMOS STARR III. THE OFFICER, CECIL THRASH IV. INCIDENT ON OCTOBER 25, 1947 V. NAACP INVOLVEMENT VI. FBI AND DEPARTMENT OF JUSTICE INVOLVEMENT VII. AUTOPSY VIII. CRIMINAL TRIAL IX. JURY INSTRUCTION X. DEPARTMENT OF JUSTICE...»

«PETITION FOR ORDER DECLARING NO ADMINISTRATION NECESSARY INSTRUCTIONS I. Specific Instructions 1. This form is to be used when filing a Petition for an Order Declaring No Administration Necessary, pursuant to O.C.G.A. § 53-2-40 et seq., and should only be used when the Decedent died intestate (without a Will).2. Unanimous consent of the heirs at law to the agreed upon division is required according to O.C.G.A. § 53-2-40 (b). 3. Signatures of heirs who acknowledge service must be sworn to...»

«U.S. GovernMent WatchliStinG: Unfair Process and Devastating consequences March 2014 U.S. Government Watchlisting: Unfair Process and Devastating Consequences Introduction The U.S. government today maintains a massive watchlisting system that risks stigmatizing hundreds of thousands of people, including American citizens, as “known or suspected terrorists” based on secret standards and secret evidence, without a meaningful process to challenge error and clear their names. The watchlists in...»

«The White Ministers’ Law and Order Statement January 16, 1963 In these times of tremendous tensions, and change in cherished patterns of life in our beloved Southland, it is essential that men who occupy places of responsibility and leadership shall speak concerning their honest convictions. We the undersigned clergymen have been chosen to carry heavy responsibility in our religious groups. We speak in a spirit of humility, and only for ourselves. We do not pretend to know all the answers,...»

«ETHICAL LESSONS FROM COURTROOM LAWYERS IN THE MOVIES By Steven O. Rosen The Rosen Law Firm, P.C. 1000 SW Broadway, Suite 1220 Portland, Oregon 97205 Telephone: (503) 525-2525 Rosen@RosenLawFirm.com www.RosenLawFirm.com for: Aviation Insurance Association 2014 AIA Annual Conference Phoenix, Arizona May 3 – 6, 2014 TABLE OF CONTENTS Page 1. INTRODUCTION 2. MOTION PRACTICE LESSON ONE: Start by telling the judge or jury what you want in a simple, direct way. COROLLARY TO LESSON ONE: Start each...»

«GEOGRAFIA OnlineTM Malaysia Journal of Society and Space 10 issue 8 (65 – 71) 65 Themed issue on tourism in new development dimension © 2014, ISSN 2180-2491 Mengurus pelancongan sempadan Malaysia-Thailand: Kesepaduan atau konflik 1 1 1 1 1 Habibah Ahmad, Hamzah Jusoh, Er Ah Choy, Amriah Buang, Sivapalan Selvadurai, 1 2 1 Nur Farahin Zainuddin, Mohd Kamarulnizam Abdullah, Sri Winarni Samsir 1 Pusat Pengajian Sosial, Pembangunan dan Persekitaran, Fakulti Sains Sosial dan Kemanusiaan,...»

«ISLAM TODAY Journal of the Islamic Educational, Scientific and Cultural Organization -ISESCOEdited in the three languages: Arabic, English and French Issue 28 27th year 1433H / 2012 ISLAM TODAY All rights reserved Address: Avenue des F.A.R. Hay Riad, P.O. Box 2275, Postcode 10104 Rabat Kingdom of Morocco Tel.: +(212) 0 5 37 56 60 52 / 5 3756 60 53 Fax: +(212) 0 5 37 56 60 12 / 5 37 56 60 13 Information Division fax: +(212) 0 5 37 71 53 27 / 71 47 21 ISESCO e-mail: isesco@isesco.org.ma Press...»

«Sunday SchoolFebruary 26, 2012 BEARING ONE ANOTHER’S BURDEN Unifying Topic: FRUITS OF REDEMPTION Lesson Text I. Walking In The Spirit (Galatians 5:22-26) II. The Spirit-Filled Life (Galatians 6:1-6) III. Reaping And Sowing (Galatians 6:7-10) The Main Thought: But the fruit of the Spirit is love, joy, peace, longsuffering, gentleness, goodness, faith, Meekness, temperance: against such there is no law.(Genesis 15:6, KJV). Unifying Principle: While faith in something or someone must come first,...»

«Judicial Review: A RESEARCH PAPER 06/44 28 SEPTEMBER 2006 short guide to claims in the Administrative Court This paper examines judicial review, a High Court Procedure for challenging administrative actions. Judicial review is a legal procedure, allowing individuals or groups to challenge in court the way that Ministers, Government Departments and other public bodies make decisions. The paper seeks to explain how claimants bring applications for judicial review and also discusses the procedures...»

«Análisis y desarrollo de los GDR en el Sistema Nacional de Salud MINISTERIO DE SANIDAD Y CONSUMO Edita y distribuye: Centro de Publicaciones MINISTERIO DE SANIDAD Y CONSUMO Paseo del Prado, 18 28014 Madrid NIPO: 351-99-047-0 Depósito Legal: AV-233-1999 Imprime: MIJÁN, Industrias Gráficas Abulenses Coordinador del proyecto Comité Director del Proyecto Alberto Núñez Feijóo Agustín Rivero Cuadrado Juan Bestard Perelló Agustín Rivero Cuadrado Rafael Mateo Rodríguez Luis Gabilondo Pujol...»

«Analytical Report PHARE RAXEN_CC Minority Education RAXEN_CC National Focal Point Latvia Latvian Centre for Human Rights and Ethnic Studies Minority Education in Latvia Vienna, 2004 DISCLAIMER: This study has been compiled by the RAXEN_CC National Focal Point of the European Monitoring Centre on Racism and Xenophobia (EUMC). The opinions expressed by the author/s do not necessarily reflect the opinion or position of the EUMC. No mention of any authority, organisation, company or individual...»

<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.